×
About 883 results

ALLMedicine™ Guillain-barre Syndrome Center

Research & Reviews  282 results

Cerebrospinal Fluid Analysis
http://emedicine.medscape.com/article/2093316-overview

Jun 16th, 2022 - Reference Range Characteristics of normal spinal fluid are below: [1, 2, 3, 4] Total volume: 150 mL Color: Colorless, clear, like water Pressure: < 20 cm H 2O Osmolarity at 37°C: 281 mOsm/L Specific gravity: 1.006 to 1.008 Acid-base balance: pH: 7...

Cerebrospinal Fluid Analysis
https://emedicine.medscape.com/article/2093316-print

Jun 16th, 2022 - Characteristics of normal spinal fluid are below:[1, 2, 3, 4] Total volume: 150 mL Color: Colorless, clear, like water Pressure: < 20 cm H 2O Osmolarity at 37°C: 281 mOsm/L Specific gravity: 1.006 to 1.008 Acid-base balance: pH: 7.28-7.32 Pco2: 47...

Cerebrospinal Fluid Analysis
https://emedicine.medscape.com/article/2093316-overview

Jun 16th, 2022 - Reference Range Characteristics of normal spinal fluid are below: [1, 2, 3, 4] Total volume: 150 mL Color: Colorless, clear, like water Pressure: < 20 cm H 2O Osmolarity at 37°C: 281 mOsm/L Specific gravity: 1.006 to 1.008 Acid-base balance: pH: 7...

Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: ...
https://doi.org/10.1016/j.annonc.2022.05.519
Annals of Oncology : Official Journal of the European Soc... Maio M, Ascierto PA et. al.

Jun 10th, 2022 - Pembrolizumab demonstrated durable antitumor activity in 233 patients with previously treated advanced microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors in the phase 2 multicohort KEYNOTE-158 (NCT026...

Acute Neurologic Complications of COVID-19 and Postacute Sequelae of COVID-19.
https://doi.org/10.1016/j.ccc.2022.03.002
Critical Care Clinics; Dangayach NS, Newcombe V et. al.

Jun 7th, 2022 - Neurologic complications can be seen in mild to severe COVID-19 with a higher risk in patients with severe COVID-19. These can occur as a direct consequence of viral infection or consequences of treatments. The spectrum ranges from non-life-threat...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  4 results

Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome
https://clinicaltrials.gov/ct2/show/NCT04053452

Jan 25th, 2022 - The purpose of this study is to determine if peripheral nerve ultrasound can be used as a supplemental tool to diagnose Guillain-Barre syndrome (GBS) in the acute setting and aid in prognostication.

Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure
https://clinicaltrials.gov/ct2/show/NCT03174964

Sep 17th, 2018 - Infertility and miscarriage ordinary events in reproductive failure in humans, as are affected one couple in every six couples of reproductive age and abortion is including in approximately 15-20% of all pregnancies. Over the decades since the beg...

Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome
https://clinicaltrials.gov/ct2/show/NCT00004833

Apr 7th, 2015 - PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are randomized to receive either human immunoglobulin infusion (IVIg) (arm I) or plasmapheresis (arm II). Arm I patients receive liquid heat-treated IVIg for 4 days starting on da...

Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine
https://clinicaltrials.gov/ct2/show/NCT00056810

Mar 25th, 2015 - Objective.- To determine the safety and efficacy of orally delivered 4-aminopyridine for motor weakness due to Guillain-Barre Syndrome (GBS) under a FDA approved protocol (IND No: 58,029). Setting.- Tertiary care outpatient rehabilitation center d...

see more →

News  50 results

 Muscle-wasting Conditions May be More Common in the UK Than Previous Estimates
https://www.medscape.com/viewarticle/968599

Feb 16th, 2022 - Tens of thousands more people in the UK could be living with neuromuscular disease (NMD) than previous estimates suggested, according to new research. A study in the journal PLOS ONE, which analysed millions of GP records, suggested that the preva...

Slight Increase in Risk of Guillain-Barre After Recombinant Zoster Vaccine Confirmed
https://www.medscape.com/viewarticle/962005

Nov 2nd, 2021 - NEW YORK (Reuters Health) - An analysis of Medicare claims data found an increased risk of Guillain-Barre syndrome (GBS) following receipt of the recombinant zoster vaccine (RZV), confirming the same "signal" from the U.S. Centers for Disease Cont...

Safety Signal for Guillain-Barre With J&J COVID-19 Shot Confirmed in Surveillance Data
https://www.medscape.com/viewarticle/960777

Oct 14th, 2021 - NEW YORK (Reuters Health) - Data from the vaccine adverse event reporting system (VAERS) show a potential "small but statistically significant safety concern" for the development of Guillain-Barre syndrome (GBS) after receipt of the Janssen/Johnso...

The Delta Factor
https://www.mdedge.com/fedprac/article/246040/coronavirus-updates/delta-factor
Cynthia Geppert, MD, MA, MPH, MSBE

Sep 13th, 2021 - Several weeks ago, I received a call from my brother who, though not a health care professional, wanted me to know he thought the public was being too critical of scientists and physicians who “are giving us the best advice they can about COVID. P.

EU Lists Rare Nerve Disorder as Side Effect of J&J COVID-19 Vaccine
https://www.medscape.com/viewarticle/955233

Jul 23rd, 2021 - (Reuters) - Europe's medicines regulator said on Thursday it had added a nerve-degenerating disorder, Guillain-Barré syndrome, as a possible rare side effect from Johnson & Johnson's COVID-19 vaccine after it reviewed 108 cases reported worldwide....

see more →

Patient Education  11 results see all →